- Home
- SA vs SUPN Comparison
SA vs SUPN Comparison
Compare SA & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SA | SUPN |
|---|---|---|
| Founded | 1979 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 2004 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SA | SUPN |
|---|---|---|
| Price | $24.18 | $41.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $59.06 | ★ $60.50 |
| AVG Volume (30 Days) | 487.1K | ★ 992.0K |
| Earning Date | 11-16-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | N/A | $23.01 |
| Revenue Next Year | N/A | $15.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.00 | $37.54 |
| 52 Week High | $40.06 | $59.68 |
Technical Indicators
Market Signals| Indicator | SA | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 36.54 | 53.58 |
| Support Level | $24.10 | $41.86 |
| Resistance Level | $28.33 | $51.59 |
| Average True Range (ATR) | 1.09 | 2.13 |
| MACD | 0.00 | 0.24 |
| Stochastic Oscillator | 26.35 | 72.38 |
Price Performance
Historical ComparisonAbout SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development-stage company involved in the exploration and development of gold properties situated in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.